“Beckman Coulter's Inhibin A assay can greatly improve resource efficiency in laboratories by providing fast, precise test results without the need for manual intervention,” said Richard Creager, vice president of Beckman Coulter's High-Sensitivity Testing Group.
The newly automated Inhibin A assay negates the need to split samples when processed in tandem with other reproductive assays on the Access® 2 or UniCel® DxI 800 Access immunoassay systems.
Hospitals and laboratories use the assay to report rapid, accurate inhibin A results that aid in the diagnosis and monitoring of various reproductive hormonal disorders. Published reports indicate the utility of inhibin A measurement as an endocrine marker for monitoring ovarian function. Beckman Coulter has an exclusive license to manufacture and market the assay.
Access Inhibin A delivers a time to first result in approximately 56 minutes and offers 28-day calibration and open-pack stability. It is standardized to the Diagnostic Systems Laboratories, Inc. (DSL) Inhibin A ELISA and can be performed using serum or plasma (EDTA, Heparin) in a sample volume of 70 µL. The liquid, ready-to-use reagent features an analytical sensitivity of less than 1 pg/mL and total imprecision of less than or equal to eight percent coefficient of variation (CV) at inhibin A concentrations greater than 30 pg/mL.
Beckman Coulter's complete family of immunoassay systems features a menu of approximately 60 assays worldwide and includes the Access 2 and UniCel DxI 800 Access immunoassay systems, which can perform up to 400 tests per hour. Access Inhibin A is the first of many high-value immunoassays expected from Beckman Coulter's acquisition of DSL. |
